{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:30:54Z","timestamp":1761975054171},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,11,13]],"date-time":"2008-11-13T00:00:00Z","timestamp":1226534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Our objective was to examine the numbers and characteristics of US pediatric adverse events (AEs) reported to the Food and Drug Administration (FDA)'s adverse event reporting system (AERS) for 5 years following implementation of the Best Pharmaceuticals for Children Act (BPCA) in 2002.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed reports in AERS received by FDA from January 1, 2003 to January 1, 2008 for overall numbers, age, gender, and seriousness of outcome in children and adults. Pediatric and adult age groups (&lt;2, 2\u201310, 11\u201317, 18\u201350, and &gt;50 years of age) were further evaluated for most frequently reported suspect drug classes and AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy\u2010two percent of 815 267 crude count reports had specified age information. Six percent of the total reports with age information reported age &lt;18 years. Numbers of AEs being reported for children have remained steady, while those for adults have increased. The proportion of serious AEs reported was similar for pediatrics as compared to adults. Frequently reported suspect drug classes noted in pediatric age groups that were not observed in adults included anticonvulsants, attention deficit hyperactivity disorder (ADHD), anti\u2010acne, and respiratory medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This overview highlights the need for strengthening the passive drug surveillance system from a pediatric perspective, as well as investing in more active surveillance systems. Drug safety initiatives to better capture risk information in order to balance the risk\/benefit of drug use in children. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1679","type":"journal-article","created":{"date-parts":[[2008,11,13]],"date-time":"2008-11-13T11:02:17Z","timestamp":1226574137000},"page":"24-27","source":"Crossref","is-referenced-by-count":40,"title":["Pediatric drug surveillance and the food and drug administration's adverse event reporting system: an overview of reports, 2003\u20132007"],"prefix":"10.1002","volume":"18","author":[{"given":"Rosemary","family":"Johann\u2010Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Wyeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith U.","family":"Cope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,11,13]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"135","volume-title":"Pharmacoepidemiology","author":"Ahmad SR","year":"2005"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.01.016"},{"key":"e_1_2_1_4_2","unstructured":"Best Pharmaceuticals for Children Act. Pub.L. No. 107\u2013109 (Jan 4 2002)http:\/\/www.fda.gov\/opacom\/laws\/pharmkids\/contents.html(accessed 8 May 2007)."},{"key":"e_1_2_1_5_2","unstructured":"FDA.Pediatric Advisory Committee meetings. FDA Office of Pediatric Therapeutics Rockville;2006. http:\/\/www.fda.gov\/oc\/opt\/PACmeetings.html (accessed 8 May 2007)."},{"key":"e_1_2_1_6_2","unstructured":"Postmarketing reporting of adverse drug experiences. 21 C.F.R. Sect. 314. 80 (2006).http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfCFR\/ CFRSearch.cfm?fr=314.80(accessed 9 May 2007)."},{"key":"e_1_2_1_7_2","unstructured":"Vector One\u00ae: National [electronic database]. Yardley (PA): Verispan LLC. Years 2002\u20132007 Extracted March2008."},{"key":"e_1_2_1_8_2","unstructured":"U.S. Census Bureau. Annual Estimates of the Population by Selected Age Groups and Sex for the United States (2006).http:\/\/www.census.gov\/popest\/archives\/(accessed January 31 2008)."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-0585"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.16.1752"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.161.3.282"},{"key":"e_1_2_1_12_2","unstructured":"WorthyKC GovernaleLA.Trends in outpatient prescription drug usage in the US 2002\u20102005 [abstract].12th Annual FDA Science Forum2006; I\u201013.http:\/\/www.accessdata.fda.gov\/scripts\/oc\/scienceforum\/sf2006\/search\/preview.cfm?keyword=worthy&abstract_id=642&type=coauthor&backto=search(accessed 8 May 2007)."},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/109158101317097728"},{"key":"e_1_2_1_14_2","unstructured":"Ouellet\u2010HellstromR KornegayC Johann\u2010LiangR.Gender\u2010differential drug risk evaluation in adolescents and young adults: examination of top 30 drug prescriptions data.12th Annual FDA Science Forum2006; I\u2010PO\u201028.http:\/\/www.accessdata.fda.gov\/scripts\/oc\/scienceforum\/sf2006\/search\/preview.cfm?keyword=johann&abstract_id=1016&type= coauthor&backto=search(accessed 8 May 2007)."},{"key":"e_1_2_1_15_2","unstructured":"GardnerS FlackM.Designing a Medical Device Surveillance Network: Report to Congress. FDA Center for Devices and Radiologic Health Rockville; Sep 1999.http:\/\/www.fda.gov\/cdrh\/postsurv\/medsun.html(accessed 8 May 2007)."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1679","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1679","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T22:24:19Z","timestamp":1700000659000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,13]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1002\/pds.1679"],"URL":"https:\/\/doi.org\/10.1002\/pds.1679","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,13]]}}}